COVID-19 vaccine safety-monitoring failures face renewed scrutiny

BMJ reporting and related analysis describe weaknesses in U.S. COVID-19 vaccine safety surveillance, including VAERS-analysis limitations, masking concerns, and absent automated alerts before myocarditis was recognized as a causal adverse effect. GCoVS provides an active-surveillance and global-capacity-building counterpoint, but remediation and the broader causal significance of the failures remain unresolved.